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Abstract
Many medicines are prescribed to the paediatric population on an unlicensed or ‘off-label’ basis because they have
not been adequately tested and/or formulated and authorized for use in appropriate paediatric age groups. Regu-
latory authorities also need to remind health professionals about the importance of their contribution towards the
process of paediatric pharmacovigilance thanks to their reporting of adverse drug reactions.
The lack of reliable data in the paediatric population is associated with specific problems including: limited avail-
ability of safety data due to the lack of clinical trials in the paediatric population; under- or over-dosing in some
age groups due to the lack of pharmacokinetics data or dose-finding studies; maturation, growth and development
of the paediatric population susceptible to drug-induced growth and development disorders as well as to delayed
ADRs not findable in adults.
Pre-marketing trials are able to provide information about the benefits of drugs but do not manage to establish a
safety profile. Spontaneous reporting of suspected ADRs become an important means to promote reasonable
warning signs.
Therefore some ADRs may be known in their qualitative aspect and quantitative aspect only after successful mar-
keting and use in the population during a “normal” use. When the drug is used in clinical practice in large unse-
lected populations, epidemiological post-marketing studies are useful as they find their major confirmation in
recalling all the events that occur during monitoring, with estimates of incidence of ADRs that can not be
obtained by spontaneous reports.
In these studies a significant role can be played by the Family Pediatricians with the participation to active phar-
macovigilance projects.
Introduction
Many medicines are prescribed to the paediatric popula-
tion on an unlicensed or ‘off-label’ basis because they
have not been adequately tested and/or formulated and
authorized for use in appropriate paediatric age groups.
Regulatory authorities also need to remind health pro-
fessionals about the importance of their contribution
towards the process of paediatric pharmacovigilance
thanks to their reporting of adverse drug reactions
(ADRs). The practice of pharmacovigilance for paedia-
tric use medicines requires special attention. Childhood
diseases and disorders may be qualitatively and quantita-
tively different from their adult equivalents. This may
affect either the benefit or the risk of therapies (or both)
with a resulting impact on the risk/benefit balance.
The lack of reliable data in the paediatric population is
associated with specific problems including: limited
availability of safety data due to the lack of clinical trials
in the paediatric population; under- or over-dosing in
some age groups due to the lack of pharmacokinetics
data or dose-finding studies; maturation, growth and
development of the paediatric population susceptible to
drug-induced growth and development disorders as well
as to delayed ADRs not findable in adults.
Pediatricians should be aware that the use of off label
drugs increases the risk of adverse reactions and they
should also try to pay much more attention when they
administer drug therapies to their patients, especially for
those categories of drugs which have clinical studies
supporting their safety and/or efficacy [1,2].
The World Health Organization defines adverse reac-
tions as harmful and unintended responses to a drug
and which occur with doses normally used in humans
for prophylaxis, diagnosis or treatment of a disease or
modifying a physiological function. It is a phenomenon
which rarely is associated with a significant impact on
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In 2001, according to a U.S. surveillance study, ADRs
were the cause of 244.000 outpatient visits of children
under 15 years of age. During an active surveillance of
63 U.S hospitals, the study of NEISS- CADES
(National Electronic Surveillance System-Cooperative
Adverse Event Surveillance project) reported that
among the above mentioned age group the incidence
of ADRs was equal to 2 out of 1000 people. Younger
children are at greatest risk. Considering this, half of
registered ADRs occur in people who are younger than
4 years of age and the risk of ADRs among children
under 5 years of age is 4 times higher than those of
children who attend schools (5.8/1000 compared to
1.1/1000). Even in Italy ADRs confirm their impact.
According to a study based on a system of active mon-
itoring of Paediatrics, about 15 out of 1000 children
developed adverse reactions [1-6].
Despite a responsible attitude of paediatricians during
the administration of medications and with an appropri-
ateness of drug prescribing, the National Network of
Pharmacovigilance (RNF) consistently underlines
adverse drug reactions (ADRs) connected to medicines
throughout the national territory [3-5].
Serious adverse reactions are rare and are generally
not observed during the paediatric clinical trial program
especially if there is a latent period before an onset or
triggering such as a change in growth. For most medi-
cines it is impossible to fully investigate rare adverse
reactions prior authorization, as it is necessary to expose
a large number of subjects to a medicinal product to eli-
cit a reaction which occurs with a low probability in the
target population.
Most of the ADRs, observed in pediatric prospective
studies, mainly effect the skin (rash, urticaria) and the
gastrointestinal system (diarrhea, nausea and vomiting),
but we can also observe systemic reactions and reactions
connected to the central nervous system. The drugs
most frequently associated with adverse reactions are
those most commonly used among young patients such
as vaccines, antibiotics, antipyretics, non steroidal anti-
inflammatory and specific products for colds and some
drugs belonging to those classes used for the gastroin-
testinal tract and metabolism [3-5]. Although the overall
incidence of data regarding the Italian situation is con-
sistent when compared to other European nations, in
some drugs we can be observe that significant differ-
ences also depend on national surgery practice.
Off- Label drugs
Among the major factors that contribute to the occur-
rence of adverse reactions in children, the off-label use,
or unlicensed, without authorization of use in children
catches the eye. The limited availability of medicines
specifically designed for the pediatric age is a reality
with which many generations of pediatricians have
learned to deal with. A reality which the practitioner has
to face every time he or she is choosing a drug grouped
with some evidence of efficacy and safety only in adults
and not in smaller patients. Less than 15% of all drugs
currently marketed and less than half of those specifi-
cally intended for children are operated on the basis of
clinical trials which demonstrate specific features of
risk-benefit balance in children [1,2,6-11]
The use of off-label or unlicensed is a therapeutic neces-
sity and an opportunity where there would be, otherwise,
a coverage of drug treatments. The highest percentages of
off-label prescriptions are registered in complex diseases
such as cancer, cardiovascular or renal diseases. In hospital
wards corresponding to these therapeutic areas, like inten-
sive care, 36-67% of children receive off-label prescrip-
tions. In clinical practice, the outpatient prescription of
off-label is 11-37% of the cases.
A systematic off-label use of drugs has been one of the
main activities of the Working Group on “Medicines
and Children “ and of the AIFA Working Pediatric
Group. An updated list of off-label drugs associated
with the availability of scientific evidence was put
together and sent to the relevant AIFA Technical Com-
mittee of Science (CTS).
The problem is that the use of off-label drugs exposes
the child to a high risk of severe adverse reactions.
There is a lack of specific formulations in extempora-
neous preparations, for example when diluting concen-
trated solutions. The risk of medication errors is 3 times
higher than those observed among adults. The incidence
of error depends on the age of the patient, the therapeu-
tic area, the setting and in most cases it is due to the
need to adapt, in a very simplistic manner, an adult
dose according to the difference in weight and body sur-
face of a child. Quoting the joint WHO-UNICEF report
of 2006: “Children are not small adults when taking a
drug.” The capacity of absorption, distribution, metabo-
lism and elimination of a drug are very different
between adults and children and they continue to
change during the stage of development. The risks
resulting from the administration of a drug that has not
been tested and proven in the pediatric population may
therefore be due to overdose (increase in adverse reac-
tions), ineffectiveness of the drug (for dosing) and use of
a formulation which is not appropriate [6-11].
A high percentage of the accesses to the emergency
room for adverse reactions, after an ingestion of an
overdose of medication, has been registered. The main
causes of overdoses are: accidental ingestion of the drug
for the lack of adult control, defective or inadequate
packaging (for example, the lack of safety lock systems),
the error in the preparation/dilution of a more concen-
trated drug. These also include the ingestion not being
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aware of the same active ingredient in drugs sold under
a different name and a different indication.
One example that continues to reach the RNF reports
of ADRs in children is of overdose of oxatomide. There
are two different packages on the market with the same
dosage form but at different concentrations (0.25% and
2.5%), which shows an increased risk of overdose linked
to an incorrect administration [3-6].
Clinical studies, evaluation and limitations
Before registration, children medication studies would be
able to reduce at least some of the adverse reactions that
are observed in young patients, especially those related to
problems of dosage, overdose or poisoning. The pharma-
ceutical industry itself has little incentive to develop
drugs and produce guidelines on doses for children
because, apart from a few therapeutic areas, the potential
market for pediatric medicines often offer marginal prof-
its and are unlikely to cover the costs of a clinical trial.
The studies are expensive and should be carried out
separately for different age groups (newborns, infants,
children, adolescents) because of the continuous meta-
bolic changes and the maturation of the apparatuses.
In order to fill the void of studies and to improve
knowledge about the efficacy profile of drugs in pedia-
trics, EMEA - according to Law 1901/2006, which
became enforceable in 2007, as well as providing guide-
lines in order to conduct studies in Pediatrics (PIP,
Pediatric Investigation Plane) - has established some
incentives for pharmaceutical companies, including the
extension of one year for the duration of the patent for
those products used for experimentation on children.
Work is underway to highlight the fundamental need of
medical treatment for children in order to identify old
molecules, which could be revised and returned to pedia-
tric use with a rational perspective, directed and imple-
mented towards those areas which are still without proper
treatment. This work has been started by the so-called
Lists of Pediatric Needs developed by the EMEA. Priority
has been established based on the severity of the disease,
the lack of an alternative therapy and the existence of
scientific data that has promoted the use of a molecule.
Spontaneous reports
Pre-marketing trials are able to provide information
about the benefits of drugs but do not manage to estab-
lish a safety profile. Therefore, spontaneous reporting of
suspected ADRs become an important means to pro-
mote reasonable warning signs: from the description of
a few cases, significant regulatory actions may derive in
order to protect pediatric age groups (nasal deconge-
stants on those banned below 12 aa, metoclopramide
prohibited below 16aa., on eyedrops containing pheny-
lephrine for mydriasis) [3-11].
Paediatricians’ case reports mainly involve vaccines
(exavalent, Anti-pneumococcal, anti-meningococcus,
Trivalent measles/mumps/rubella) because they are
used in most pediatric subjects or either because they
involve the duty to report any type reaction including
those which are expected not to be serious. Vaccines,
which are then followed by frequency reports of phar-
maceuticals used by children: antibiotics, antipyretics,
specific products for colds and some belonging to
those classes used for the gastrointestinal tract and
metabolism [3-6].
The reports are verified and compared with data from
reports presented in international networks EudraVigi-
lance VigiMed Organization, but also on the basis of
epidemiological studies and periodic drug safety data. In
Italy, the activity of spontaneous reporting in children is
very low: in recent years paediatric data-reporting has
stood at around 1.6 to 1.8 percent, compared with 8% of
total reporting [3-5].
Reasons may be different: 1. a non spread of a iatro-
genic disease culture over the years 2. not having under-
stood the real benefits that the spontaneous reporting
system can create for the community in terms of redu-
cing the risks of patients and saving resources 3. the
lack of education, “mindset”, “courage” of pediatricians
as they tend “not to see” an injury caused, even though
unintentionally, to their patients. In support of the
above, there is the fact that, during the course of univer-
sity studies and schools of specialization, inadequate
attention is given to pediatric pharmacology, pharma-
covigilance (FVG) and pathology of drugs, this causing
methodological and behavioral uncertainty [1,2,11].
Other reasons can be the fear to report something
already known and therefore considered of little value
or exposure when speaking about off-label use of drugs;
the lack of meaningful feedback on clinical practice; the
perception that the compiling of report forms is
complicated.
With regards to this, family pediatricians ask compa-
nies which produce software for children to simplify the
procedure of reporting by inserting a specific link in
their database program.
A major cause of underreporting by family pediatri-
cians is determined by the behavior of families, when
facing adverse reactions due to a non-rational use of
drugs (often caused by the use of “Do it yourself”
drugs), as they prefer to go directly to the Emergency
Department after an ingestion of an overdose of medica-
tion (see Off-label drugs).
Post-marketing studies and long term follow up
(LTFU)
Even when conducted with a thorough and careful test-
ing prior to the marketing of a drug, their characteristics
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are not always able to provide the information required
in order to determine the safety profile of a drug used
in the general population. This limited number of sub-
jects includes and usually does not exceed 10,000, not
to mention the adverse reactions (for example, with an
incidence of 1 in 100,000 users) or to identify the real
impact on public health. The short course of clinical
trials does not disclose reactions with long latency, such
as those related to chronic use. The patients selected
are generally healthy and therefore have not been trea-
ted with other drugs.
Epidemiological post-marketing studies, directed
towards the recovery of all the events which occur dur-
ing monitoring, give much more reliable estimates of
the risk of ADRs than those resulting from spontaneous
reports [1,2,6-11].
“Risk management” programs promoted by industries
are often under funded, therefore there is a need to
improve drug monitoring programs by means of an
“active” observation, this enabling the system to antici-
pate possible identifications of efficacy and safety pro-
blems. This would then help to plan appropriate actions
in due time reducing risks for the community. The pri-
mary objective of a good FVG activity is the definition
of the risk/benefit ratio. For a more precise and consis-
tent verification of this report there are continuous
investments in key inputs, and there is the contribution
of a careful and continuous scientific evaluation of what
are called “weak signals”. Greater the transparency and
simplification of procedures in the FVG field, the greater
the hope of positive benefits in terms of public health
and improved safety [1,2,6-11].
Another important aspect to be considered is the lack
or the few studies which assess long-term ADRs in
pediatrics probably because there are organizational and
logistical difficulties (the cases refer to significant drop-
outs in the studies carried out so far).
In order to complete the safety profile of a drug it is
necessary to carry out post-marketing epidemiological
studies aimed at a long-term recovery of all the events
that occur during monitoring. In these studies a signif-
icant role can be played by the family pediatrician with
the reporting of suspected ADRs and with the partici-
pation to active pharmacovigilance projects.
With regards to this, family pediatricians have orga-
nized a network of pediatric investigators (FIMP -
Medicines for Children Research Network) spread
throughout the country and involved exclusively in
post-marketing studies and LTFU (Long Term Follow
Up) studies according to the Law - DM 139/2001 (this
Law expresses the possibility of family pediatricians to
perform Phase 3 and Phase 4 in their clinical trials).
Pro active FVG: challenges and opportunities for
Family Paediatricians
Despite the increasing accuracy of testing, preclinical and
clinical trials which are required during the development
of any active substance for the purpose of ensuring their
safety in clinical applications, some ADRs may be known
in their qualitative aspect (type of side effect) and quantita-
tive aspect (true incidence in the treated population) only
after successful marketing and use in the population dur-
ing a “normal” use and not in those selected for the clini-
cal trials. When the drug is used in clinical practice in
large unselected populations, epidemiological post-mar-
keting studies are useful as they find their major confirma-
tion in recalling all the events that occur during
monitoring, with estimates of incidence of ADRs that can
not be obtained by spontaneous reports.
From here the need to improve surveillance programs
through the experience of use of drugs and resources of
surveillance systems called “pro-active”. Moving from
the focus on a “defensive” regulation based on a type of
surveillance of “passive” reactions to a now newer con-
cept, FVG has to take into account the course that
accompanies the whole life-cycle management of the
drug. The primary objective of a good FVG activity is
the definition of the risk/benefit. For a precise and con-
sistent verification of this report, there are continuous
investments in key inputs with the contribution of all
the careful and continuous scientific evaluation of spon-
taneous reports. Having a proactive approach means to
organize FP in terms of methods and resources so that
the system is able to anticipate the possible identifica-
tion of efficacy and safety problems in order to plan
appropriate actions in due time reducing community
risks [1,2,8,11].
From all these considerations it is clear that we should
move in different directions. There is the need to awa-
ken FPs to a culture of iatrogenic disease, to the report-
ing of ADRs and to the proper use of reporting forms.
On the other hand there is a need for a greater culture
of research in pediatric pharmacology leading towards
an increasingly pro-active FVG. Moreover, we must be
able to seize the opportunities independently from
scientific research institutions (AIFA, Contract Depart-
ment, FVG Regional funds) proposing safety studies on
drugs for pediatric trials with short term follow-ups and
particularly in the long run.
The organization of specific training courses should
meet the following objectives: 1) promote the culture of
iatrogenic disease in pediatrics 2) provide information
on the benefit-risk profile of drugs 3) promote sponta-
neous reporting 4) improve the short and long term fol-
low-up for a complete evaluation of ADRs.
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A special FIMP working group, Pharmacovigilance
Group: a) organizes training courses b) improves the
Network of Pharmacovigilance in order to enable a
synergy when working with the RNF and raising aware-
ness to the alert among the FP c) provides a national
Survey (drugs and/or pathology Registers) d) partici-
pates, when called for independent research, to evaluate
the risk/benefit of drugs in pediatrics e) fosters close
collaboration with the national regulatory activities
through the participation in the AIFA Pediatric Working
Group.
In this regard, the Group has already organized a
Master Course “Pharmacovigilance in Pediatrics” which
is part of a “pilot training and educational project”.
Another important event was a whole session in the II
National Congress of Naples FIMP-2008 on “Medicines
for children and Pharmacovigilance”. In all Courses for
FP-Investigators (according to the Law - DM 139/2001),
which have been organized throughout the territory,
specific ADRs sessions have been included. They all had
the aim of raising the awareness of Family Paediatricians
speaking about a culture of diseases caused by drugs.
Future prospects for family pediatricians
A future path to follow in pediatrics is undoubtedly
towards the synergy and coordination of all components
of Pediatrics (universities, hospitals, territories) for the
organization of research projects and post-marketing
programs. The starting point must necessarily be cul-
tural: an implementation of the culture of iatrogenic dis-
ease and a careful assessment of the significance of post-
marketing studies by Family Paediatricians. Of course,
all these supported by capacity building of the Network
of FP-Investigators which is central to epidemiological
studies-observational and DBPC-RCT studies on medi-
cines for children. The creation of a specific database
managed and coordinated by the FPs with medium and
long term follow-up results becomes strategic and very
important for a careful and correct evaluation of ADRs.
Last but not least, what must also be mentioned, is the
fact that with the FP there would be fewer drop-outs in
LTFU if there is a taking charge of children and estab-
lishing a close relationship with families.
The ultimate goal is the coordination of the Italian
network with national networks of other EU countries
and then the becoming part of the EMEA “Network of
the Networks’.
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